Simponi vs Omvoh for Ulcerative Colitis: Which Is Better?

Simponi and Omvoh represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained UC approval in October 2023 based on LUCENT-1 and LUCENT-2, making it the first IL-23 p19-selective biologic approved for UC. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and distinctive urgency data. This guide walks through the simponi vs omvoh ulcerative colitis comparison.

Anti-TNF vs IL-23 p19 Mechanism

Simponi binds TNF-alpha and reduces inflammation throughout the body and in the colon. Omvoh binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 is a central driver of Th17-mediated inflammation in UC. The golimumab vs mirikizumab distinction shapes both speed of onset and the long-term safety profile. Simponi's broader TNF blockade produces rapid systemic anti-inflammatory effects. Omvoh's selective IL-23 inhibition produces strong efficacy with a cleaner infection profile.

LUCENT Trial UC Evidence

Simponi's UC efficacy rests on PURSUIT-SC (induction) and PURSUIT-M (maintenance). Omvoh's UC efficacy rests on LUCENT-1 (induction) and LUCENT-2 (maintenance). LUCENT-1 showed clinical remission rates of 24.2% on Omvoh versus 13.3% on placebo at week 12, with endoscopic remission, symptomatic remission, and bowel urgency improvement also significantly better. LUCENT-2 showed 49.9% of Omvoh patients in clinical remission at week 40 versus 25.1% on placebo. No head-to-head trial has directly compared Simponi with Omvoh in UC. Indirect comparisons suggest Omvoh produces comparable or potentially stronger clinical remission rates, with particular advantage on bowel urgency outcomes.

Onset of Action

Simponi produces meaningful UC response by week 6 based on PURSUIT-SC. Omvoh's UC onset produces meaningful response by week 12 based on LUCENT-1. For UC patients with severe, active symptoms who need rapid control, Simponi's faster onset is often preferred. For patients in less acute states or those weighing long-term safety, Omvoh's response trajectory is generally acceptable.

Bowel Urgency Outcomes

A distinctive feature of Omvoh's data is bowel urgency improvement. LUCENT showed significant improvement in urgency numerical rating scale scores at both induction and maintenance, which matters to patients whose daily life is disrupted by sudden urgency episodes. Simponi's UC program did not capture bowel urgency with the same rigor, though real-world data supports general symptom improvement on golimumab. For UC patients whose primary quality-of-life concern is urgency, Omvoh's outcome profile is distinctive.

Safety and Infection Risk

Simponi carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Omvoh's UC safety data from LUCENT has been favorable, consistent with IL-23 p19 class effects. Long-term data for IL-23 p19 biologics consistently shows lower rates of serious systemic infection than anti-TNFs. For simponi vs omvoh side effects in patients with infection concerns or comorbidities, Omvoh's narrower mechanism often looks more favorable. Both drugs require TB and hepatitis B screening before starting.

Administration and Dosing

Simponi for UC uses 200 mg SC at week 0, 100 mg at week 2, and then 100 mg every 4 weeks for maintenance, per Janssen's prescribing information. Simponi is all-SC throughout. Omvoh for UC uses IV induction at 300 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 200 mg every 4 weeks, per Lilly's Omvoh prescribing information. For UC patients comparing administration, Simponi is fully SC, while Omvoh requires IV induction before transitioning to SC maintenance. Both drugs maintain on every-4-week SC cadence.

Anti-TNF Experienced Patients

For patients who have failed or lost response to a prior anti-TNF, a mechanism switch to Omvoh is supported by LUCENT-1 data, which included biologic-experienced UC patients. Cycling within the anti-TNF class typically delivers lower response rates than changing mechanism classes. For UC patients with prior anti-TNF exposure, Omvoh often has better expected response.

Extraintestinal Manifestations

Simponi, as an anti-TNF, treats UC-associated extraintestinal manifestations like peripheral arthritis, ankylosing spondylitis, and certain skin conditions. Omvoh is newer and does not have the same breadth of extraintestinal data. For UC patients with significant extraintestinal involvement, Simponi's anti-TNF class coverage may be preferred.

Choosing With Your GI

For a UC patient deciding between Simponi and Omvoh, Simponi tends to win on faster onset, fully SC administration throughout, and extraintestinal manifestation coverage. Omvoh tends to win on long-term safety, distinctive bowel urgency outcomes from LUCENT, and performance in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency episodes, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.